Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Real World Evidence Solutions Market Size, Share, Trends, and Forecast, 2026-2033 | Regulatory Adoption and Data Growth Fuel a USD 6.04 Billion Opportunity

globenewswire.com
IQV IQVIA is mentioned as a company in the competitive landscape of the real world evidence solutions market. The article does not provide specific sentiment towards IQVIA's performance or prospects. TMO Thermo Fisher Scientific is mentioned as the parent company of PPD Inc., which is listed in the competitive landscape for real world evidence solutions. No specific sentiment is expressed. ORCL Oracle is listed as a competitor in the real world evidence solutions market. The article does not provide any specific sentiment or analysis regarding Oracle's performance or position. UNH UnitedHealth Group is mentioned as the parent company of Optum Inc., listed as a competitor in the real world evidence solutions market. No specific sentiment is expressed. CDNS Cognizant is listed as a competitor in the real world evidence solutions market. The article does not provide any specific sentiment or analysis regarding Cognizant's performance.

Global Real World Evidence Solutions Market Size, Share, Trends, and Forecast, 2026-2033 | Regulatory Adoption and Data Growth Fuel a USD 6.04 Billion Opportunity Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component, Therapeutic Area, Application, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global real world evidence solutions market was valued at an estimated USD 3.04 billion in 2025 and is projected to reach USD 6.04 billion by 2033. The market is expected to expand at a CAGR of 9.08% from 2026 to 2033, supported by increasing R&D investment, broader applications of real-world evidence (RWE), favorable regulatory initiatives, and the rapid growth of real-world data.

Regulatory bodies worldwide are increasingly incorporating real-world evidence into drug and medical device evaluations. RWE is being used to supplement clinical trial findings, support regulatory submissions, accelerate product approvals, and strengthen patient safety monitoring. Clearer regulatory frameworks are also encouraging pharmaceutical, biotechnology, and medical device companies to integrate RWE solutions into healthcare research, product development, and post-market surveillance.

Recent policy developments demonstrate growing institutional support for RWE adoption. In December 2025, the U.S. Food and Drug Administration removed a longstanding requirement for real-world evidence submitted with drug and device applications to contain identifiable individual patient data. Under the updated approach, de-identified datasets from registries, insurance claims, and electronic health record networks may be evaluated on a case-by-case basis during regulatory reviews.

In January 2025, the UK's Medicines and Healthcare Products Regulatory Agency launched its pilot Real-World Evidence (RWE) Scientific Dialogue Programme under its 2024-27 Data Strategy. The initiative gives innovators access to confidential discussions and a "safe harbour" workshop designed to improve evidence-generation strategies and clarify regulatory and health-technology assessment expectations. These measures are expected to strengthen confidence in RWE methodologies and facilitate their use across products, therapeutic areas, and regulatory pathways.

The expanding volume of real-world data is another major driver of market growth. Health-related data is increasing at a compound annual rate of 36%, with electronic health records, insurance claims, disease registries, wearable technologies, pharmacy records, and patient-reported outcomes contributing to greater scale and granularity. Improvements in data integration, interoperability, and advanced analytics allow RWE platforms to convert these datasets into actionable insights. Pharmaceutical companies, healthcare payers, providers, and research organizations can consequently generate more representative and timely evidence for drug development, regulatory decision-making, reimbursement strategies, and value-based care.

Market Segmentation Covered in the Report

The report forecasts global, regional, and country-level revenue growth and analyzes real world evidence solutions market trends across sub-segments from 2021 to 2033. The market is segmented by component, application, end use, therapeutic area, and region.

Country-level analysis includes the U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, Israel, UAE, and Kuwait.

Strategic Value of the Report

The report provides decision-makers with market intelligence for evaluating opportunities in the global real world evidence solutions market. Its coverage supports strategic planning for healthcare companies, clinical research organizations, payers, providers, technology vendors, and investors seeking to respond to evolving data requirements and regulatory expectations.

Key Attributes:

Key Topics Covered:

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Component

1.2.2. Application

1.2.3. End Use

1.2.4. Therapeutic Area

1.2.5. Regional scope

1.2.6. Estimates and forecasts timeline

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased database

1.4.2. internal database

1.4.3. Secondary sources

1.4.4. Primary research

1.4.5. Details of primary research

1.5. Information or Data Analysis

1.5.1. Data analysis models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity flow analysis

1.8. List of Secondary Sources

1.9. List of Primary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Component and Application outlook

2.2.2. End use and Therapeutic Area outlook

2.2.3. Regional outlook

2.3. Competitive Insights

Chapter 3. Real World Evidence Solutions Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Related/ancillary market outlook

3.2. Market Dynamics

3.2.1. Market driver analysis

3.2.2. Market restraint analysis

3.2.3. Market Opportunity analysis

3.2.4. Market Challenges analysis

3.3. Case Study Insights

3.3.1. Case Study 1: Real-World Evidence Enables Regulatory Pathway for Label Expansion

3.3.2. Case Study 2

3.3.3. Case Study 3

3.3.4. Case Study 4

3.3.5. Case Study 5

3.4. Real World Evidence Solutions Market Analysis Tools

3.4.1. Industry Analysis - Porter's Five Forces Analysis

3.4.2. PESTEL Analysis

3.4.3. Pricing Model Analysis

Chapter 4. Real World Evidence Solutions Market: Component Estimates & Trend Analysis

4.1. Global Real World Evidence Solutions Market: Component Dashboard

4.2. Global Real World Evidence Solutions Market: Component Movement Analysis

4.3. Global Real World Evidence Solutions Market by Component, Revenue (USD Million)

4.4. Services

4.4.1. Services market estimates and forecasts, 2021-2033 (USD Million)

4.5. Data sets Systems

4.5.1. Data sets systems market estimates and forecasts, 2021-2033 (USD Million)

4.5.2. Clinical Settings Data

4.5.3. Claims Data

4.5.4. Pharmacy Data

4.5.5. Patient-Powered Data

Chapter 5. Real World Evidence Solutions Market: Application Estimates & Trend Analysis

5.1. Global Real World Evidence Solutions Market: Application Dashboard

5.2. Global Real World Evidence Solutions Market: Application Movement Analysis

5.3. Global Real World Evidence Solutions Market Estimates and Forecasts, by Application, Revenue (USD Million)

5.4. Drug Development & Approvals

5.4.1. Drug development & approval market estimates and forecasts, 2021-2033 (USD Million)

5.5. Medical Device Development & Approvals

5.5.1. Medical device development & approvals market estimates and forecasts, 2021-2033 (USD Million)

5.6. Reimbursement/Coverage and Regulatory Decision Making

5.6.1. Reimbursement/Coverage and Regulatory Decision Making market estimates and forecasts, 2021-2033 (USD Million)

5.7. Post Market Safety & Adverse Events Monitoring

5.7.1. Post Market Safety & Adverse Events Monitoring market estimates and forecasts, 2021-2033 (USD Million)

Chapter 6. Real World Evidence Solutions Market: End Use Estimates & Trend Analysis

6.1. Global Real World Evidence Solutions Market: End Use Dashboard

6.2. Global Real World Evidence Solutions Market: End Use Movement Analysis

6.3. Global Real World Evidence Solutions Market Estimates and Forecasts, by End Use, Revenue (USD Million)

6.4. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)

6.4.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) market estimates and forecasts, 2021-2033 (USD Million)

6.4.2. Clinical research

6.4.3. Supervised Commercial (inclusive of marketing, etc.)

6.4.4. HEOR

6.4.5. Others (market access, etc.)

6.5. Processing Healthcare Payers

6.5.1. Processing Healthcare Payers market estimates and forecasts, 2021-2033 (USD Million)

6.5.2. Healthcare Providers

6.5.3. Others

Chapter 7. Real World Evidence Solutions Market: Therapeutic Area Estimates & Trend Analysis

7.1. Global Real World Evidence Solutions Market: Therapeutic Area Dashboard

7.2. Global Real World Evidence Solutions Market: Therapeutic Area Movement Analysis

7.3. Global Real World Evidence Solutions Market Estimates and Forecasts, by Therapeutic Area, Revenue (USD Million)

7.4. Oncology

7.4.1. Oncology market estimates and forecasts, 2021-2033 (USD Million)

7.5. Cardiology

7.5.1. Cardiology market estimates and forecasts, 2021-2033 (USD Million)

7.6. Neurology

7.6.1. Neurology market estimates and forecasts, 2021-2033 (USD Million)

7.7. Psychiatry

7.7.1. Psychiatry market estimates and forecasts, 2021-2033 (USD Million)

7.8. Respiratory

7.8.1. Respiratory market estimates and forecasts, 2021-2033 (USD Million)

7.9. Other Therapeutic Areas (Immunology, Gastroenterology, etc.)

7.9.1. Other Therapeutic Areas (Immunology, Gastroenterology, etc.) market estimates and forecasts, 2021-2033 (USD Million)

Chapter 8. Real World Evidence Solutions Market: Regional Estimates & Trend Analysis by Component, Application, End Use, and Therapeutic Area

8.1. Regional Dashboard

8.2. Market Size, & Forecasts Trend Analysis, 2021-2033:

8.3. North America

8.3.1. U.S.

8.3.2. Canada

8.3.3. Mexico

8.4. Europe

8.4.1. UK

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Denmark

8.4.7. Sweden

8.4.8. Norway

8.5. Asia-Pacific

8.5.1. Japan

8.5.2. China

8.5.3. India

8.5.4. South Korea

8.5.5. Thailand

8.5.6. Australia

8.6. Latin America

8.6.1. Brazil

8.6.2. Argentina

8.7. MEA

8.7.1. South Africa

8.7.2. Saudi Arabia

8.7.3. Israel

8.7.4. UAE

8.7.5. Kuwait

Chapter 9. Competitive Landscape

9.1. Company Market Position Analysis

9.2. Company Market Share Analysis, 2025

9.3. Company Evaluation Quadrant

9.4. Company Categorization

9.5. Strategy Mapping

9.6. Company Profiles/Listing

9.6.1. IQVIA

9.6.2. Merative

9.6.3. PPD Inc. (now part of Thermo Fisher)

9.6.4. Parexel International Corporation

9.6.5. IPLC Plc

9.6.6. Oracle

9.6.7. Syneos Health

9.6.8. Cegedim Health Data

9.6.9. Medpace

9.6.10. Optum Inc. (UnitedHealth Group)

9.6.11. SAS Institute Inc.

9.6.12. Cognizant

9.6.13. Aetion, Inc. (acquired by Datavant in May 2025)

9.6.14. Flatiron Health

9.6.15. Cytel Inc.

9.6.16. Trinity

9.6.17. NTT Data Inc.

List of Tables [123]

List of Figures [83]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/opfqen

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.